Bioemtech
Founded 2013 · 53 employees on LinkedIn · 1 known investors
Find your way into Bioemtech
Bioemtech provides in vitro cell-based assays and laboratory services for drug discovery and stem cell therapy applications, utilizing cell lines and standardized protocols to measure cytotoxicity, biological activity, and biochemical mechanisms for pharmaceutical research.
Also known as BIOEMTECH
Investors · 1
Company profile
researched Aug 2026BIOEMTECH is a provider of preclinical research capabilities aimed at accelerating the development of candidate drugs toward clinical translation, with a stated focus on radiopharmaceutical innovation. Its offering spans three product and service lines: preclinical services delivered on a contract research organization (CRO) basis, imaging scanners described as desktop systems, and software tools that accompany the imaging platforms.
Alongside its commercial activities, the company runs educational and outreach programming, including an annual preclinical workshop held in Athens, Greece, webinars on topics such as the route of radiopharmaceuticals toward clinical translation, and in-person meetings and conference presences in the United States.
Business model
BIOEMTECH combines contract preclinical research services with sales of imaging instrumentation and accompanying software tools.
Latest developments
In May 2026 BIOEMTECH announced a strategic partnership with LabLogic for North America and held a webinar on radiopharmaceuticals' path to clinical translation. In June 2026 it participated in the SNMMI Annual Meeting in Los Angeles and hosted a Lunch & Learn meeting in Boston. Its sixth annual preclinical workshop is scheduled for October 13-16, 2026 in Athens, Greece.
▸Full profile — technology, go-to-market, geography
Technology
The company develops desktop-format preclinical imaging scanners and associated software tools used in radiopharmaceutical and drug research.
Go-to-market
The company reaches customers directly and through channel partnerships, including a strategic partnership with LabLogic for North America announced in May 2026, and through conference participation such as the SNMMI Annual Meeting, webinars, its own annual preclinical workshop in Athens and Lunch & Learn meetings in the United States.
Scientists and organizations conducting preclinical drug and radiopharmaceutical research.
Geography
The annual workshop is held in Athens, Greece, and the company engages the North American market through a distribution partnership and events in Boston and Los Angeles.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsCompany-hosted annual preclinical workshop scheduled for 13-16 October 2026 in Athens, Greece.
Company-organized Lunch & Learn meeting held in Boston, USA.
BIOEMTECH announced a strategic partnership with LabLogic covering the North American market.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- Bioemtechbioemtech.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bioemtech do?
- BIOEMTECH supports radiopharmaceutical and drug development with preclinical CRO services, desktop imaging scanners and software.
- Who are Bioemtech's investors?
- Bioemtech's investors include Metavallon VC.